Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Jeffrey Deignan is active.

Publication


Featured researches published by Jeffrey Deignan.


Journal of Medicinal Chemistry | 2012

Structure-based design of novel inhibitors of the MDM2-p53 interaction.

Yosup Rew; Daqing Sun; Felix Gonzalez-Lopez de Turiso; Michael D. Bartberger; Hilary P. Beck; Jude Canon; Ada Chen; David Chow; Jeffrey Deignan; Brian M. Fox; Darin Gustin; Xin Huang; Min Jiang; Xianyun Jiao; Lixia Jin; Frank Kayser; David J. Kopecky; Yihong Li; Mei-Chu Lo; Alexander M. Long; Klaus Michelsen; Jonathan D. Oliner; Tao Osgood; Mark L. Ragains; Anne Y. Saiki; Steve Schneider; Maria M. Toteva; Peter Yakowec; Xuelei Yan; Qiuping Ye

Structure-based rational design led to the discovery of novel inhibitors of the MDM2-p53 protein-protein interaction. The affinity of these compounds for MDM2 was improved through conformational control of both the piperidinone ring and the appended N-alkyl substituent. Optimization afforded 29 (AM-8553), a potent and selective MDM2 inhibitor with excellent pharmacokinetic properties and in vivo efficacy.


Journal of Medicinal Chemistry | 2014

Discovery of AMG 232, a Potent, Selective, and Orally Bioavailable MDM2–p53 Inhibitor in Clinical Development

Daqing Sun; Zhihong Li; Yosup Rew; Michael W. Gribble; Michael D. Bartberger; Hilary P. Beck; Jude Canon; Ada Chen; Xiaoqi Chen; David Chow; Jeffrey Deignan; Jason Duquette; John Eksterowicz; Benjamin Fisher; Brian M. Fox; Jiasheng Fu; Ana Z. Gonzalez; Felix Gonzalez-Lopez de Turiso; Jonathan B. Houze; Xin Huang; Min Jiang; Lixia Jin; Frank Kayser; Jiwen Liu; Mei-Chu Lo; Alexander M. Long; Brian Lucas; Lawrence R. McGee; Joel McIntosh; Jeff Mihalic

We recently reported the discovery of AM-8553 (1), a potent and selective piperidinone inhibitor of the MDM2-p53 interaction. Continued research investigation of the N-alkyl substituent of this series, focused in particular on a previously underutilized interaction in a shallow cleft on the MDM2 surface, led to the discovery of a one-carbon tethered sulfone which gave rise to substantial improvements in biochemical and cellular potency. Further investigation produced AMG 232 (2), which is currently being evaluated in human clinical trials for the treatment of cancer. Compound 2 is an extremely potent MDM2 inhibitor (SPR KD = 0.045 nM, SJSA-1 EdU IC50 = 9.1 nM), with remarkable pharmacokinetic properties and in vivo antitumor activity in the SJSA-1 osteosarcoma xenograft model (ED50 = 9.1 mg/kg).


Bioorganic & Medicinal Chemistry Letters | 2014

Optimization beyond AMG 232: discovery and SAR of sulfonamides on a piperidinone scaffold as potent inhibitors of the MDM2-p53 protein-protein interaction.

Yingcai Wang; Jiang Zhu; Jiwen Liu; Xiaoqi Chen; Jeff Mihalic; Jeffrey Deignan; Ming Yu; Daqing Sun; Frank Kayser; Lawrence R. McGee; Mei-Chu Lo; Ada Chen; Jing Zhou; Qiuping Ye; Xin Huang; Alexander M. Long; Peter Yakowec; Jonathan D. Oliner; Steven H. Olson; Julio C. Medina

We recently reported on the discovery of AMG 232, a potent and selective piperidinone inhibitor of the MDM2-p53 interaction. AMG 232 is being evaluated in human clinical trials for cancer. Continued exploration of the N-alkyl substituent of this series, in an effort to optimize interactions with the MDM2 glycine-58 shelf region, led to the discovery of sulfonamides such as compounds 31 and 38 that have similar potency, hepatocyte stability and rat pharmacokinetic properties to AMG 232.


Bioorganic & Medicinal Chemistry Letters | 2008

Optimization of the heterocyclic core of the quinazolinone-derived CXCR3 antagonists.

An-Rong Li; Michael G. Johnson; Jiwen Liu; Xiaoqi Chen; Xiaohui Du; Jeffrey T. Mihalic; Jeffrey Deignan; Darin Gustin; Jason Duquette; Zice Fu; Liusheng Zhu; Andrew P. Marcus; Phillipe Bergeron; Lawrence R. McGee; Jay Danao; Bryan Lemon; Teresa Arazas Carabeo; Timothy J. Sullivan; Ji Ma; Liang Tang; George Tonn; Tassie L. Collins; Julio C. Medina


Archive | 2006

Aryl nitrile compounds and compositions and their uses in treating inflammatory and related disorders

Philippe Bergeron; Xiaoqi Chen; Xiaohui Du; Jeffrey Deignan; Jason Duquette; Darin Gustin; Julio C. Medina; Jeffrey T. Mihalic; George Tonn


Bioorganic & Medicinal Chemistry Letters | 2008

Design and optimization of imidazole derivatives as potent CXCR3 antagonists

Xiaohui Du; Xiaoqi Chen; Jeffrey T. Mihalic; Jeffrey Deignan; Jason Duquette; An-Rong Li; Bryan Lemon; Ji Ma; Shichang Miao; Karen Ebsworth; Timothy J. Sullivan; George Tonn; Tassie L. Collins; Julio C. Medina


Archive | 2008

Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors

Richard V. Connors; Kang Dai; John Eksterowicz; Pingchen Fan; Benjamin Fisher; Jiasheng Fu; Kexue Li; Zhihong Li; Lawrence R. McGee; Rajiv Sharma; Xiaodong Wang; Dustin L. McMinn; Jeffrey T. Mihalic; Jeffrey Deignan


Archive | 2006

Anti-inflammatory aryl nitrile compounds

Philippe Bergeron; Xiaoqi Chen; Xiaohui Du; Jeffrey Deignan; Jason Duquette; Darin Gustin; Julio C. Medina; Jeffrey T. Mihalic; George Tonn


Archive | 2005

Tetrahydroquinazolin-4(3h)-one-related and tetrahydropyrido[2,3-d]pyrimidin-4(3h)-one-related compounds, compositions and methods for their use

Zice Fu; Michael G. Johnson; An-Rong Li; Andrew P. Marcus; Julio C. Medina; Philippe Bergeron; Xiaoqi Chen; Xiaohui Du; Jeffrey Deignan; Jason Duquette; Darin Gustin; Jeffrey T. Mihalic; Jiwen Liu


Journal of Medicinal Chemistry | 2014

Discovery of AMG 925, a FLT3 and CDK4 Dual Kinase Inhibitor with Preferential Affinity for the Activated State of FLT3

Zhihong Li; Xianghong Wang; John Eksterowicz; Michael W. Gribble; Grace Q. Alba; Merrill Ayres; Timothy J. Carlson; Ada Chen; Xiaoqi Chen; Robert Cho; Richard V. Connors; Michael DeGraffenreid; Jeffrey Deignan; Jason Duquette; Pingchen Fan; Benjamin Fisher; Jiasheng Fu; Justin N. Huard; Jacob Kaizerman; Kathleen S. Keegan; Cong Li; Kexue Li; Yunxiao Li; Lingming Liang; Wen Liu; Sarah E. Lively; Mei-Chu Lo; Ji Ma; Dustin L. McMinn; Jeffrey T. Mihalic

Collaboration


Dive into the Jeffrey Deignan's collaboration.

Researchain Logo
Decentralizing Knowledge